{"gene":"ERMN","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2006,"finding":"Ermin (ERMN) is an oligodendrocyte-specific cytoskeletal protein localized to the outer cytoplasmic lip of the myelin sheath and paranodal loops in mature nerve. In cultured oligodendrocytes, Ermin concentrates at the tips of F-actin-rich processes ('Ermin spikes'). Ectopic expression of full-length Ermin, but not of a mutant lacking its actin-binding domain, induced numerous cell protrusions and pronounced morphological changes, demonstrating that the actin-binding domain is required for cytoskeletal rearrangement activity.","method":"Microarray expression profiling of oligodendrocyte-ablated mice, immunolocalization in mature nerve and cultured oligodendrocytes, ectopic expression of wild-type and actin-binding domain deletion mutants in cultured cells","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — domain-deletion mutagenesis combined with cellular morphology readout and in vivo localization; foundational mechanistic study replicated by subsequent independent labs","pmids":["16421295"],"is_preprint":false},{"year":2010,"finding":"Human Ermin (hErmin) promotes arborization and cytoskeletal rearrangement in cultured COS-7 cells when expressed as full-length protein, but truncated mutants lacking the actin-binding domain fail to do so, confirming that the actin-binding domain is the functional effector domain for morphological changes.","method":"Ectopic expression of full-length and truncated hErmin constructs in COS-7 cells with morphological readout","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain-deletion mutagenesis with clear functional readout, single lab replicating the founding observation with human ortholog","pmids":["20934411"],"is_preprint":false},{"year":2019,"finding":"ERMN is a primary target of disrupted folate metabolism caused by sevoflurane anesthesia. Sevoflurane downregulates thymidylate synthase (TYMS), reducing folate availability, which epigenetically suppresses ERMN expression and impairs myelination. Restoration of ERMN expression via brain-specific AAV-PHP.EB delivery, or systemic folic acid supplementation, rescued myelination deficits and alleviated cognitive impairment in mice, placing ERMN downstream of the TYMS–folate–epigenetic axis in developmental myelination.","method":"Transcriptome profiling and genome-wide DNA methylation analysis in sevoflurane-exposed rhesus macaques and mice; AAV-mediated ERMN rescue in vivo; folic acid supplementation rescue; cognitive behavioral testing","journal":"EBioMedicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (transcriptomics, methylomics, in vivo rescue with AAV and pharmacological intervention) across two species with clear functional endpoints","pmids":["31060905"],"is_preprint":false},{"year":2020,"finding":"Ermin maintains myelin sheath integrity and is required for normal saltatory conduction. Aged Ermn-knockout mice develop aberrant myelin architecture (splitting of myelin layers, peeling from axons, breakdown of myelinated fibers) and impaired motor coordination. Mechanistically, Ermin associates with the myosin phosphatase Rho-interacting protein (Mprip/p116RIP) and inactivates RhoA, a GTPase controlling cytoskeletal rearrangement in differentiating oligodendrocytes. Ermn knockout also accelerated cuprizone-induced demyelination.","method":"Constitutive Ermn-knockout mouse generation; electron microscopy of myelin ultrastructure; motor coordination behavioral assays; cuprizone demyelination model; co-immunoprecipitation of Ermin with p116RIP; RhoA activity assays","journal":"Glia","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP identifying p116RIP as binding partner, RhoA activity assay, KO mouse with defined ultrastructural and behavioral phenotypes, multiple orthogonal methods in one study","pmids":["32530539"],"is_preprint":false},{"year":2022,"finding":"Loss of Ermin causes de-compacted and fragmented myelin sheaths and slower nerve conduction in vivo. RNA-seq of the corpus callosum of aged Ermin-deficient mice revealed inflammatory activation, corroborated by increased microgliosis and astrogliosis. Ermin-knockout mice show increased susceptibility to immune-mediated (EAE) demyelination. A rare inactivating ERMN mutation was identified in multiple sclerosis patients, supporting an 'inside-out' model of inflammatory dysmyelination initiated by myelin instability.","method":"Ermn-knockout mouse model; electrophysiology (nerve conduction velocity); RNA-seq of corpus callosum; immunohistochemistry for microglia and astrocyte markers; EAE (experimental autoimmune encephalomyelitis) susceptibility assay; human ERMN sequencing in MS patients","journal":"Brain pathology (Zurich, Switzerland)","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse with electrophysiological, transcriptomic, and histological phenotypes plus human genetic evidence; multiple orthogonal methods","pmids":["35285112"],"is_preprint":false},{"year":2016,"finding":"Rare genetic variants causing hypomethylation (meSNVs) at the ERMN locus are significantly associated with autism spectrum disorder (ASD). Resequencing revealed a significant load of deleterious mutations in ERMN in ASD cases compared with controls, and cis-acting methylation changes correlated with altered ERMN expression, implicating epigenetic regulation of ERMN in ASD susceptibility.","method":"Genome-wide methylation array (450K Illumina) in ASD patients vs. controls; blood RNA-seq; case-control association study; targeted resequencing of ERMN","journal":"Translational psychiatry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — multiple genomic methods in a sizeable cohort but no direct functional experiment on the protein mechanism; establishes epigenetic regulation of ERMN but not the protein's mechanistic action","pmids":["27404287"],"is_preprint":false},{"year":2021,"finding":"In the cuprizone demyelination/remyelination mouse model, the density of Ermin-immunopositive oligodendrocytes decreases after one week of cuprizone exposure and increases during remyelination in the corpus callosum. In MS lesions, the proportion of ermin+ cells relative to Nogo-A+ cells is higher in remyelinated areas than in non-remyelinated or normal-appearing white matter, indicating that a relatively higher proportion of Ermin immunopositivity marks recent or ongoing remyelination.","method":"Cuprizone mouse model with time-course immunohistochemistry; immunostaining of MS post-mortem tissue with Ermin, Nogo-A, O4, and O1 markers","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — quantitative in vivo localization experiment with functional context (remyelination state) replicated in both animal model and human tissue, single lab","pmids":["34437581"],"is_preprint":false},{"year":2021,"finding":"ERMN mRNA expression is significantly downregulated in peripheral blood of ASD patients compared with healthy controls, with the effect reaching significance specifically in male subjects, supporting a role for ERMN dysregulation in ASD pathogenesis.","method":"Quantitative real-time PCR of ERMN in peripheral blood of ASD patients and matched healthy controls","journal":"Frontiers in molecular neuroscience","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single method (qRT-PCR), expression data only, no direct mechanistic experiment on the protein","pmids":["34349621"],"is_preprint":false},{"year":2019,"finding":"ERMN expression is significantly decreased in peripheral blood leukocytes of relapsing-remitting multiple sclerosis (RR-MS) patients compared with healthy controls, consistent with Ermin's proposed role in maintaining myelination.","method":"Quantitative RT-PCR of ERMN transcript in peripheral blood of RR-MS patients vs. controls","journal":"Metabolic brain disease","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single method (qRT-PCR), expression correlation only, no direct mechanistic protein experiment","pmids":["31123898"],"is_preprint":false}],"current_model":"ERMN encodes Ermin, an oligodendrocyte-specific actin-binding cytoskeletal protein localized to the outer cytoplasmic lip of the myelin sheath and paranodal loops; its actin-binding domain is required for inducing cell protrusions and cytoskeletal rearrangements in oligodendrocytes, and Ermin maintains myelin integrity by binding the myosin phosphatase co-factor p116RIP (Mprip) and inactivating RhoA, with loss of Ermin causing myelin decompaction, inflammatory gliosis, impaired nerve conduction, and increased susceptibility to demyelination, while its expression is epigenetically regulated downstream of the folate–TYMS axis during developmental myelination."},"narrative":{"mechanistic_narrative":"ERMN encodes Ermin, an oligodendrocyte-specific actin-binding cytoskeletal protein that concentrates at the outer cytoplasmic lip of the myelin sheath and at paranodal loops, where it drives the cytoskeletal rearrangements underlying myelin morphogenesis and maintenance [PMID:16421295]. In cultured cells, Ermin localizes to the tips of F-actin-rich processes and its actin-binding domain is required to induce cell protrusions and arborization; deletion of this domain abolishes the morphological activity in both rodent and human orthologs [PMID:16421295, PMID:20934411]. Mechanistically, Ermin associates with the myosin phosphatase Rho-interacting protein Mprip/p116RIP and inactivates RhoA, linking it to GTPase-controlled cytoskeletal remodeling in differentiating oligodendrocytes [PMID:32530539]. Loss of Ermin produces de-compacted, fragmented, and split myelin, slowed saltatory nerve conduction, motor deficits, inflammatory gliosis, and heightened susceptibility to cuprizone- and immune-mediated (EAE) demyelination, defining Ermin as a maintainer of myelin integrity whose failure can initiate inflammatory dysmyelination [PMID:32530539, PMID:35285112]. Ermin immunopositivity tracks active remyelination in both the cuprizone model and human MS lesions [PMID:34437581], and a rare inactivating ERMN mutation has been identified in multiple sclerosis patients, supporting an 'inside-out' model of demyelination driven by intrinsic myelin instability [PMID:35285112]. ERMN expression is epigenetically regulated downstream of the TYMS–folate axis during developmental myelination, with folate disruption suppressing ERMN and impairing myelination that is rescued by restoring ERMN or supplementing folate [PMID:31060905].","teleology":[{"year":2006,"claim":"Establishing what Ermin is and how it acts: identifying it as an oligodendrocyte-specific protein whose actin-binding domain drives cytoskeletal rearrangement answered whether ERMN had a defined cellular function in myelinating cells.","evidence":"Microarray profiling of oligodendrocyte-ablated mice, immunolocalization in nerve and cultured oligodendrocytes, and ectopic expression of wild-type vs. actin-binding-domain-deletion mutants","pmids":["16421295"],"confidence":"High","gaps":["Did not identify direct binding partners beyond F-actin association","Mechanism linking actin binding to myelin assembly in vivo not yet defined"]},{"year":2010,"claim":"Confirming that the human ortholog retains the same domain-dependent activity established conservation of Ermin's cytoskeletal effector function across species.","evidence":"Ectopic expression of full-length and truncated human Ermin constructs in COS-7 cells with morphological readout","pmids":["20934411"],"confidence":"Medium","gaps":["Performed in a non-oligodendrocyte heterologous cell line","No identification of binding partners or signaling output"]},{"year":2016,"claim":"Linking ERMN epigenetic regulation to a neurodevelopmental disorder tested whether ERMN dysregulation has disease relevance beyond myelin biology.","evidence":"Genome-wide methylation array, blood RNA-seq, case-control association, and targeted resequencing of ERMN in ASD cohorts","pmids":["27404287"],"confidence":"Medium","gaps":["No functional experiment connecting methylation changes to protein-level mechanism","Association does not establish causality in ASD"]},{"year":2019,"claim":"Placing ERMN downstream of the TYMS–folate–epigenetic axis explained how environmental and metabolic perturbation suppresses myelination through ERMN.","evidence":"Transcriptomics and methylomics in sevoflurane-exposed macaques and mice, with AAV-mediated ERMN rescue and folic acid supplementation plus cognitive testing","pmids":["31060905"],"confidence":"High","gaps":["Precise epigenetic mark and machinery suppressing ERMN not pinpointed","Direct molecular link between ERMN restoration and myelin repair mechanism not resolved"]},{"year":2019,"claim":"Correlating reduced ERMN transcript with relapsing-remitting MS provided a peripheral biomarker consistent with its myelin-maintenance role.","evidence":"Quantitative RT-PCR of ERMN in peripheral blood leukocytes of RR-MS patients vs. controls","pmids":["31123898"],"confidence":"Low","gaps":["Single-method expression correlation only","Peripheral blood may not reflect CNS Ermin biology","No mechanistic link to disease causation"]},{"year":2020,"claim":"Defining the in vivo loss-of-function phenotype and identifying the Mprip/p116RIP–RhoA axis revealed the signaling mechanism by which Ermin maintains myelin.","evidence":"Constitutive Ermn-knockout mice with EM ultrastructure, motor assays, cuprizone demyelination, reciprocal Co-IP with p116RIP, and RhoA activity assays","pmids":["32530539"],"confidence":"High","gaps":["Structural basis of the Ermin–p116RIP interaction unknown","How RhoA inactivation is spatially coupled to myelin compaction not resolved"]},{"year":2021,"claim":"Showing Ermin immunopositivity tracks remyelination state established it as an in vivo marker of active myelin repair.","evidence":"Time-course immunohistochemistry in the cuprizone model and immunostaining of MS post-mortem lesions with Ermin, Nogo-A, O4, and O1 markers","pmids":["34437581"],"confidence":"Medium","gaps":["Correlative marker association, not a functional test of Ermin in remyelination","Single-lab study"]},{"year":2021,"claim":"Documenting reduced ERMN transcript in ASD peripheral blood, with male-specific significance, reinforced the disease-association signal from the methylation study.","evidence":"Quantitative real-time PCR of ERMN in peripheral blood of ASD patients vs. matched controls","pmids":["34349621"],"confidence":"Low","gaps":["Single-method expression data with no protein-level mechanism","Peripheral blood relevance to CNS uncertain"]},{"year":2022,"claim":"Connecting myelin instability to inflammatory activation and human genetic risk supported an 'inside-out' model in which intrinsic Ermin loss initiates demyelinating disease.","evidence":"Ermn-knockout mice with nerve conduction electrophysiology, corpus callosum RNA-seq, gliosis immunohistochemistry, EAE susceptibility, and ERMN sequencing in MS patients","pmids":["35285112"],"confidence":"High","gaps":["Causality of the identified ERMN mutation in MS not functionally proven","Mechanism linking myelin decompaction to inflammatory recruitment not detailed"]},{"year":null,"claim":"How Ermin's actin-binding and p116RIP/RhoA signaling are mechanistically coupled to myelin compaction, and how its loss is sensed to trigger neuroinflammation, remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No structural model of Ermin or its complexes","Sensor/effector pathway linking myelin instability to gliosis undefined","Functional validation of human ERMN disease mutations lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[0,1]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3]}],"localization":[{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[0]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,2]}],"complexes":[],"partners":["MPRIP","RHOA"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8TAM6","full_name":"Ermin","aliases":["Juxtanodin","JN"],"length_aa":284,"mass_kda":32.8,"function":"Plays a role in cytoskeletal rearrangements during the late wrapping and/or compaction phases of myelinogenesis as well as in maintenance and stability of myelin sheath in the adult. May play an important role in late-stage oligodendroglia maturation, myelin/Ranvier node formation during CNS development, and in the maintenance and plasticity of related structures in the mature CNS (By similarity)","subcellular_location":"Cytoplasm, cytoskeleton","url":"https://www.uniprot.org/uniprotkb/Q8TAM6/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ERMN","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ERMN","total_profiled":1310},"omim":[{"mim_id":"610072","title":"ERMIN; ERMN","url":"https://www.omim.org/entry/610072"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":596.2}],"url":"https://www.proteinatlas.org/search/ERMN"},"hgnc":{"alias_symbol":["JN","ERMIN"],"prev_symbol":["KIAA1189"]},"alphafold":{"accession":"Q8TAM6","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TAM6","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TAM6-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TAM6-F1-predicted_aligned_error_v6.png","plddt_mean":57.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ERMN","jax_strain_url":"https://www.jax.org/strain/search?query=ERMN"},"sequence":{"accession":"Q8TAM6","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8TAM6.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8TAM6/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TAM6"}},"corpus_meta":[{"pmid":"38377995","id":"PMC_38377995","title":"XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1.","date":"2024","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/38377995","citation_count":148,"is_preprint":false},{"pmid":"39510125","id":"PMC_39510125","title":"Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.","date":"2024","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/39510125","citation_count":116,"is_preprint":false},{"pmid":"16421295","id":"PMC_16421295","title":"Ermin, a myelinating oligodendrocyte-specific protein that regulates cell morphology.","date":"2006","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16421295","citation_count":97,"is_preprint":false},{"pmid":"39024099","id":"PMC_39024099","title":"Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39024099","citation_count":70,"is_preprint":false},{"pmid":"15782132","id":"PMC_15782132","title":"Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15782132","citation_count":62,"is_preprint":false},{"pmid":"31060905","id":"PMC_31060905","title":"Disrupted folate metabolism with anesthesia leads to myelination deficits mediated by epigenetic regulation of ERMN.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/31060905","citation_count":55,"is_preprint":false},{"pmid":"39259045","id":"PMC_39259045","title":"Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages.","date":"2024","source":"Emerging microbes & infections","url":"https://pubmed.ncbi.nlm.nih.gov/39259045","citation_count":54,"is_preprint":false},{"pmid":"39379369","id":"PMC_39379369","title":"Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39379369","citation_count":49,"is_preprint":false},{"pmid":"39231977","id":"PMC_39231977","title":"Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39231977","citation_count":48,"is_preprint":false},{"pmid":"38302341","id":"PMC_38302341","title":"SARS-CoV-2 evolution from the BA.2.86 to JN.1 variants: unexpected consequences.","date":"2024","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38302341","citation_count":41,"is_preprint":false},{"pmid":"38591890","id":"PMC_38591890","title":"Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.","date":"2024","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/38591890","citation_count":40,"is_preprint":false},{"pmid":"39446667","id":"PMC_39446667","title":"Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages - United States, May 2023-September 2024.","date":"2024","source":"MMWR. Morbidity and mortality weekly report","url":"https://pubmed.ncbi.nlm.nih.gov/39446667","citation_count":40,"is_preprint":false},{"pmid":"29700636","id":"PMC_29700636","title":"Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).","date":"2018","source":"International journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29700636","citation_count":40,"is_preprint":false},{"pmid":"39081516","id":"PMC_39081516","title":"The rising SARS-CoV-2 JN.1 variant: evolution, infectivity, immune escape, and response strategies.","date":"2024","source":"MedComm","url":"https://pubmed.ncbi.nlm.nih.gov/39081516","citation_count":38,"is_preprint":false},{"pmid":"39013463","id":"PMC_39013463","title":"Spike structures, receptor binding, and immune escape of recently circulating SARS-CoV-2 Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants.","date":"2024","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/39013463","citation_count":37,"is_preprint":false},{"pmid":"12218078","id":"PMC_12218078","title":"Establishment and characterization of a novel human desmoplastic small round cell tumor cell line, JN-DSRCT-1.","date":"2002","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12218078","citation_count":36,"is_preprint":false},{"pmid":"40136024","id":"PMC_40136024","title":"Neutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants.","date":"2025","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/40136024","citation_count":30,"is_preprint":false},{"pmid":"27404287","id":"PMC_27404287","title":"Genetic and epigenetic methylation defects and implication of the ERMN gene in autism spectrum disorders.","date":"2016","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/27404287","citation_count":30,"is_preprint":false},{"pmid":"39339934","id":"PMC_39339934","title":"AlphaFold2 Modeling and Molecular Dynamics Simulations of the Conformational Ensembles for the SARS-CoV-2 Spike Omicron JN.1, KP.2 and KP.3 Variants: Mutational Profiling of Binding Energetics Reveals Epistatic Drivers of the ACE2 Affinity and Escape Hotspots of Antibody Resistance.","date":"2024","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/39339934","citation_count":28,"is_preprint":false},{"pmid":"39875585","id":"PMC_39875585","title":"T cell immune evasion by SARS-CoV-2 JN.1 escapees targeting two cytotoxic T cell epitope hotspots.","date":"2025","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39875585","citation_count":24,"is_preprint":false},{"pmid":"39282390","id":"PMC_39282390","title":"Neutralization and Stability of JN.1-derived LB.1, KP.2.3, KP.3 and KP.3.1.1 Subvariants.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39282390","citation_count":24,"is_preprint":false},{"pmid":"38812550","id":"PMC_38812550","title":"Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasion.","date":"2024","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/38812550","citation_count":24,"is_preprint":false},{"pmid":"38257802","id":"PMC_38257802","title":"Timely Monitoring of SARS-CoV-2 RNA Fragments in Wastewater Shows the Emergence of JN.1 (BA.2.86.1.1, Clade 23I) in Berlin, Germany.","date":"2024","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/38257802","citation_count":24,"is_preprint":false},{"pmid":"39375326","id":"PMC_39375326","title":"Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39375326","citation_count":20,"is_preprint":false},{"pmid":"38826376","id":"PMC_38826376","title":"Characteristics of JN.1-derived SARS-CoV-2 subvariants SLip, FLiRT, and KP.2 in neutralization escape, infectivity and membrane fusion.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38826376","citation_count":20,"is_preprint":false},{"pmid":"39896217","id":"PMC_39896217","title":"The JN.1 variant of COVID-19: immune evasion, transmissibility, and implications for global health.","date":"2025","source":"Therapeutic advances in infectious disease","url":"https://pubmed.ncbi.nlm.nih.gov/39896217","citation_count":19,"is_preprint":false},{"pmid":"38583825","id":"PMC_38583825","title":"Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.","date":"2024","source":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","url":"https://pubmed.ncbi.nlm.nih.gov/38583825","citation_count":19,"is_preprint":false},{"pmid":"38428429","id":"PMC_38428429","title":"Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBD.","date":"2024","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38428429","citation_count":18,"is_preprint":false},{"pmid":"20934411","id":"PMC_20934411","title":"Human Ermin (hErmin), a new oligodendrocyte-specific cytoskeletal protein related to epileptic seizure.","date":"2010","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/20934411","citation_count":18,"is_preprint":false},{"pmid":"39121195","id":"PMC_39121195","title":"SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines.","date":"2024","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39121195","citation_count":18,"is_preprint":false},{"pmid":"32530539","id":"PMC_32530539","title":"Ermin is a p116RIP -interacting protein promoting oligodendroglial differentiation and myelin maintenance.","date":"2020","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/32530539","citation_count":16,"is_preprint":false},{"pmid":"35285112","id":"PMC_35285112","title":"Ermin deficiency leads to compromised myelin, inflammatory milieu, and susceptibility to demyelinating insult.","date":"2022","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35285112","citation_count":16,"is_preprint":false},{"pmid":"16772508","id":"PMC_16772508","title":"10.1093/jn/136.7.2090S.","date":"2006","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/16772508","citation_count":16,"is_preprint":false},{"pmid":"38678055","id":"PMC_38678055","title":"Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1.","date":"2024","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38678055","citation_count":16,"is_preprint":false},{"pmid":"38574739","id":"PMC_38574739","title":"Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.","date":"2024","source":"Med (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/38574739","citation_count":16,"is_preprint":false},{"pmid":"29378189","id":"PMC_29378189","title":"JN-2, a C-X-C motif chemokine receptor 3 antagonist, ameliorates arthritis progression in an animal model.","date":"2018","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29378189","citation_count":15,"is_preprint":false},{"pmid":"38543838","id":"PMC_38543838","title":"Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1.","date":"2024","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/38543838","citation_count":14,"is_preprint":false},{"pmid":"38622986","id":"PMC_38622986","title":"JN.1 variant in enduring COVID-19 pandemic: is it a variety of interest (VoI) or variety of concern (VoC)?","date":"2024","source":"Hormone molecular biology and clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38622986","citation_count":13,"is_preprint":false},{"pmid":"31123898","id":"PMC_31123898","title":"Down-regulation of ERMN expression in relapsing remitting multiple sclerosis.","date":"2019","source":"Metabolic brain disease","url":"https://pubmed.ncbi.nlm.nih.gov/31123898","citation_count":12,"is_preprint":false},{"pmid":"39738039","id":"PMC_39738039","title":"Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39738039","citation_count":12,"is_preprint":false},{"pmid":"39864525","id":"PMC_39864525","title":"Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients.","date":"2025","source":"Antiviral research","url":"https://pubmed.ncbi.nlm.nih.gov/39864525","citation_count":12,"is_preprint":false},{"pmid":"39732637","id":"PMC_39732637","title":"Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya.","date":"2024","source":"BMC infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/39732637","citation_count":11,"is_preprint":false},{"pmid":"39562542","id":"PMC_39562542","title":"Intranasal delivery of a subunit protein vaccine provides protective immunity against JN.1 and XBB-lineage variants.","date":"2024","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/39562542","citation_count":10,"is_preprint":false},{"pmid":"40056804","id":"PMC_40056804","title":"mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice.","date":"2025","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/40056804","citation_count":10,"is_preprint":false},{"pmid":"24879594","id":"PMC_24879594","title":"Over-expression of a proline specific aminopeptidase from Aspergillus oryzae JN-412 and its application in collagen degradation.","date":"2014","source":"Applied biochemistry and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/24879594","citation_count":10,"is_preprint":false},{"pmid":"38850530","id":"PMC_38850530","title":"Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA.2.86, EG.5.1, and JN.1.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38850530","citation_count":10,"is_preprint":false},{"pmid":"38304689","id":"PMC_38304689","title":"Navigating Novel Uncertainties of COVID-19: The Rise of the JN.1 Variant.","date":"2024","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/38304689","citation_count":9,"is_preprint":false},{"pmid":"39468971","id":"PMC_39468971","title":"XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.","date":"2024","source":"Alimentary pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/39468971","citation_count":9,"is_preprint":false},{"pmid":"39080396","id":"PMC_39080396","title":"Emergence of SARS-CoV-2 omicron variant JN.1 in Tamil Nadu, India - Clinical characteristics and novel mutations.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39080396","citation_count":8,"is_preprint":false},{"pmid":"39553825","id":"PMC_39553825","title":"Potent neutralization by a RBD antibody with broad specificity for SARS-CoV-2 JN.1 and other variants.","date":"2024","source":"Npj viruses","url":"https://pubmed.ncbi.nlm.nih.gov/39553825","citation_count":7,"is_preprint":false},{"pmid":"38646375","id":"PMC_38646375","title":"Appearance and Prevalence of JN.1 SARS-CoV-2 Variant in India and Its Clinical Profile in the State of Maharashtra.","date":"2024","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/38646375","citation_count":7,"is_preprint":false},{"pmid":"38677090","id":"PMC_38677090","title":"FLip mutations (L455F + F456L) in newly emerging VOI, JN.1: Its antibody and immune escape.","date":"2024","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38677090","citation_count":7,"is_preprint":false},{"pmid":"35964410","id":"PMC_35964410","title":"Investigation into the anti-airway inflammatory role of the PI3Kγ inhibitor JN-PK1: An in vitro and in vivo study.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35964410","citation_count":7,"is_preprint":false},{"pmid":"40000611","id":"PMC_40000611","title":"A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants.","date":"2025","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/40000611","citation_count":6,"is_preprint":false},{"pmid":"34349621","id":"PMC_34349621","title":"Expression Analysis of Ermin and Listerin E3 Ubiquitin Protein Ligase 1 Genes in Autistic Patients.","date":"2021","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34349621","citation_count":6,"is_preprint":false},{"pmid":"40298448","id":"PMC_40298448","title":"Comparative analysis of replication and immune evasion among SARS-CoV-2 subvariants BA.2.86, JN.1, KP.2, and KP.3.","date":"2025","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/40298448","citation_count":6,"is_preprint":false},{"pmid":"39026832","id":"PMC_39026832","title":"Atomistic Prediction of Structures, Conformational Ensembles and Binding Energetics for the SARS-CoV-2 Spike JN.1, KP.2 and KP.3 Variants Using AlphaFold2 and Molecular Dynamics Simulations: Mutational Profiling and Binding Free Energy Analysis Reveal Epistatic Hotspots of the ACE2 Affinity and Immune Escape.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39026832","citation_count":6,"is_preprint":false},{"pmid":"39908098","id":"PMC_39908098","title":"Rapid restoration of potent neutralization activity against the latest Omicron variant JN.1 via AI rational design and antibody engineering.","date":"2025","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/39908098","citation_count":6,"is_preprint":false},{"pmid":"34676516","id":"PMC_34676516","title":"Expression Analysis of Ermin and Listerin E3 Ubiquitin Protein Ligase 1 Genes in the Periphery of Patients with Schizophrenia.","date":"2021","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/34676516","citation_count":5,"is_preprint":false},{"pmid":"38779718","id":"PMC_38779718","title":"SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.","date":"2024","source":"Emerging microbes & infections","url":"https://pubmed.ncbi.nlm.nih.gov/38779718","citation_count":5,"is_preprint":false},{"pmid":"40985731","id":"PMC_40985731","title":"Evolution of BA.2.86 to JN.1 reveals that functional changes in non-structural viral proteins are required for fitness of SARS-CoV-2.","date":"2025","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/40985731","citation_count":5,"is_preprint":false},{"pmid":"41012604","id":"PMC_41012604","title":"Pathogenicity of SARS-CoV-2 Omicron Subvariants JN.1, KP.2, and EG.5.1 in K18-hACE2 Transgenic Mice.","date":"2025","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/41012604","citation_count":5,"is_preprint":false},{"pmid":"40035925","id":"PMC_40035925","title":"A promising mRNA vaccine derived from the JN.1 spike protein confers protective immunity against multiple emerged Omicron variants.","date":"2025","source":"Molecular biomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/40035925","citation_count":5,"is_preprint":false},{"pmid":"41381428","id":"PMC_41381428","title":"Pathogenicity, virological features, and immune evasion of SARS-CoV-2 JN.1-derived variants including JN.1.7, KP.2, KP.3, and KP.3.1.1.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41381428","citation_count":4,"is_preprint":false},{"pmid":"41350251","id":"PMC_41350251","title":"Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccines.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41350251","citation_count":4,"is_preprint":false},{"pmid":"34437581","id":"PMC_34437581","title":"A higher proportion of ermin-immunopositive oligodendrocytes in areas of remyelination.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34437581","citation_count":4,"is_preprint":false},{"pmid":"40639176","id":"PMC_40639176","title":"Neutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC.","date":"2025","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/40639176","citation_count":4,"is_preprint":false},{"pmid":"39018495","id":"PMC_39018495","title":"Protective Non-neutralizing anti-N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA.2.86-JN.1 with Superfluous In Vivo Protection against JN.1 Due to Attenuated Virulence.","date":"2024","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/39018495","citation_count":4,"is_preprint":false},{"pmid":"15725679","id":"PMC_15725679","title":"Pattern of compensatory expression of voltage-dependent Ca2+ channel alpha1 and beta subunits in brain of N-type Ca2+ channel alpha1B subunit gene-deficient mice with a CBA/JN genetic background.","date":"2005","source":"Experimental animals","url":"https://pubmed.ncbi.nlm.nih.gov/15725679","citation_count":4,"is_preprint":false},{"pmid":"40042313","id":"PMC_40042313","title":"XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies.","date":"2025","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/40042313","citation_count":4,"is_preprint":false},{"pmid":"39772110","id":"PMC_39772110","title":"T Cell Responses to BA.2.86 and JN.1 SARS-CoV-2 Variants in Elderly Subjects.","date":"2024","source":"Vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/39772110","citation_count":3,"is_preprint":false},{"pmid":"39471972","id":"PMC_39471972","title":"Integrated all-atom and coarse-grained simulations uncover structural, dynamics and energetic shifts in SARS-CoV-2 JN.1 and BA.2.86 variants.","date":"2024","source":"Acta tropica","url":"https://pubmed.ncbi.nlm.nih.gov/39471972","citation_count":3,"is_preprint":false},{"pmid":"16774125","id":"PMC_16774125","title":"Enhanced expression of Ca2+ channel alpha1A and beta4 subunits and phosphorylated tyrosine hydroxylase in the adrenal gland of N-type Ca2+ channel alpha1B subunit-deficient mice with a CBA/JN genetic background.","date":"2006","source":"Comparative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16774125","citation_count":3,"is_preprint":false},{"pmid":"39776396","id":"PMC_39776396","title":"Evaluating the Anti-inflammatory Potential of JN-KI3: The Therapeutic Role of PI3Kγ-Selective Inhibitors in Asthma Treatment.","date":"2025","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/39776396","citation_count":3,"is_preprint":false},{"pmid":"40022017","id":"PMC_40022017","title":"JN.1 variants circulating in Italy from October 2023 to April 2024: genetic diversity and immune recognition.","date":"2025","source":"BMC infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/40022017","citation_count":2,"is_preprint":false},{"pmid":"39108735","id":"PMC_39108735","title":"Immunogen characterization reveals an intrinsic hindrance in eliciting neutralizing antibodies against JN.1 variant.","date":"2024","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/39108735","citation_count":2,"is_preprint":false},{"pmid":"38717854","id":"PMC_38717854","title":"Unveiling the emergence of SARS-CoV-2 JN.1 sub-variant: Insights from the first cases at Charles Nicolle Hospital, Tunisia.","date":"2024","source":"Acta microbiologica et immunologica Hungarica","url":"https://pubmed.ncbi.nlm.nih.gov/38717854","citation_count":2,"is_preprint":false},{"pmid":"40605422","id":"PMC_40605422","title":"Longitudinal Innate and Heterologous Adaptive Immune Responses to SARS-CoV-2 JN.1 in Transplant Recipients With Prior Omicron Infection: Limited Neutralization but Robust CD4+ T-Cell Activity.","date":"2025","source":"Transplant infectious disease : an official journal of the Transplantation Society","url":"https://pubmed.ncbi.nlm.nih.gov/40605422","citation_count":2,"is_preprint":false},{"pmid":"39591144","id":"PMC_39591144","title":"STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease.","date":"2024","source":"Vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/39591144","citation_count":2,"is_preprint":false},{"pmid":"39221683","id":"PMC_39221683","title":"SARS-CoV-2 JN.1 variant: a short review.","date":"2024","source":"Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace","url":"https://pubmed.ncbi.nlm.nih.gov/39221683","citation_count":1,"is_preprint":false},{"pmid":"38559216","id":"PMC_38559216","title":"Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38559216","citation_count":1,"is_preprint":false},{"pmid":"40545672","id":"PMC_40545672","title":"Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals.","date":"2025","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/40545672","citation_count":1,"is_preprint":false},{"pmid":"40482468","id":"PMC_40482468","title":"An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variant.","date":"2025","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/40482468","citation_count":1,"is_preprint":false},{"pmid":"39772248","id":"PMC_39772248","title":"Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant Recipients.","date":"2024","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/39772248","citation_count":1,"is_preprint":false},{"pmid":"38699322","id":"PMC_38699322","title":"Emergence of SARS-CoV-2 Omicron Variant JN.1 in Tamil Nadu, India - Clinical Characteristics and Novel Mutations.","date":"2024","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38699322","citation_count":1,"is_preprint":false},{"pmid":"39765094","id":"PMC_39765094","title":"Macromolecular interaction mechanism of the bacteriocin EntDD14 with the receptor binding domain (RBD) for the inhibition of SARS-CoV-2 and the JN.1 variant: Biomedical study based on elastic networks, stochastic Markov models, and macromolecular volumetric analysis.","date":"2024","source":"Biophysical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39765094","citation_count":1,"is_preprint":false},{"pmid":"41012630","id":"PMC_41012630","title":"Long-Term Genomic Surveillance and Immune Escape of SARS-CoV-2 in the Republic of Korea, with a Focus on JN.1-Derived Variants.","date":"2025","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/41012630","citation_count":1,"is_preprint":false},{"pmid":"40599320","id":"PMC_40599320","title":"Enhanced reverse zoonotic potential and immune evasion by omicron JN.1 variant.","date":"2025","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/40599320","citation_count":0,"is_preprint":false},{"pmid":"40556423","id":"PMC_40556423","title":"TMEM106B Supports Viral Entry and Syncytia Formation Mediated by the Spike Proteins From Omicron BA.2.86 and JN.1.","date":"2025","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/40556423","citation_count":0,"is_preprint":false},{"pmid":"40408899","id":"PMC_40408899","title":"Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by different COVID-19 vaccine types: Insights into protection against wildtype, Delta and JN.1 omicron strains.","date":"2025","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/40408899","citation_count":0,"is_preprint":false},{"pmid":"41832695","id":"PMC_41832695","title":"The JN.1 Variant: Emergence and Global Spread.","date":"2026","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/41832695","citation_count":0,"is_preprint":false},{"pmid":"38746414","id":"PMC_38746414","title":"Potent neutralization by a receptor binding domain monoclonal antibody with broad specificity for SARS-CoV-2 JN.1 and other variants.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38746414","citation_count":0,"is_preprint":false},{"pmid":"39263330","id":"PMC_39263330","title":"Rapid identification of SARS CoV-2 omicron sub-variant JN.1 (BA.2.86.1.1) with mass spectrometry.","date":"2024","source":"Journal of mass spectrometry and advances in the clinical lab","url":"https://pubmed.ncbi.nlm.nih.gov/39263330","citation_count":0,"is_preprint":false},{"pmid":"38939989","id":"PMC_38939989","title":"Exploring New COVID-19 Incertitude: JN.1 Variant- JN.1: The Queer Bird among Omicron Sublineages.","date":"2025","source":"Infectious disorders drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/38939989","citation_count":0,"is_preprint":false},{"pmid":"39205166","id":"PMC_39205166","title":"Semi-Covariance Coefficient Analysis of Spike Proteins from SARS-CoV-2 and Its Variants Omicron, BA.5, EG.5, and JN.1 for Viral Infectivity, Virulence and Immune Escape.","date":"2024","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/39205166","citation_count":0,"is_preprint":false},{"pmid":"42248900","id":"PMC_42248900","title":"SARS-CoV-2 Omicron BA.2.86 and JN.1 expand tropism in human proximal intestinal epithelium.","date":"2026","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/42248900","citation_count":0,"is_preprint":false},{"pmid":"41676134","id":"PMC_41676134","title":"Comparable immune escape capacity for NB.1 with that of JN.1 variant and survey of infection with severe acute respiratory syndrome coronavirus 2 variants among Chinese Felis silvestris catus.","date":"2026","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41676134","citation_count":0,"is_preprint":false},{"pmid":"40575649","id":"PMC_40575649","title":"Alpha to JN.1 variants: SARS-CoV-2 genomic analysis unfolding its various lineages/sublineages evolved in Chhattisgarh, India from 2020 to 2024.","date":"2025","source":"World journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/40575649","citation_count":0,"is_preprint":false},{"pmid":"41316988","id":"PMC_41316988","title":"Antigenic drift in SARS-CoV-2: diminished vaccine protection in pediatric populations against Omicron and its JN.1 subvariant.","date":"2025","source":"Expert review of vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/41316988","citation_count":0,"is_preprint":false},{"pmid":"41874023","id":"PMC_41874023","title":"Discovery of Anti-SARS-CoV-2 XBB.1.5 and JN.1 Variant-Specific Monoclonal Single-Domain Antibodies from a Synthetic Library.","date":"2026","source":"Antibodies (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/41874023","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55694,"output_tokens":2805,"usd":0.104579,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9930,"output_tokens":3113,"usd":0.063738,"stage2_stop_reason":"end_turn"},"total_usd":0.168317,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"Looking through the corpus, I need to identify papers about the canonical ERMN/ERMIN protein (an oligodendrocyte-specific cytoskeletal protein). The vast majority of papers are about SARS-CoV-2 JN.1 variant (a COVID-19 variant where \"JN\" is used as an abbreviation/alias for the viral lineage, not the gene). Papers about JN-DSRCT-1 (a cell line), JN-2 (a CXCR3 antagonist), JN-PK1/JN-KI3 (PI3K inhibitors), and CBA/JN (mouse strain) are also unrelated to ERMN.\n\nThe relevant ERMN papers are: 3, 6, 18, 29, 31, 32, 39, 55, 59, 66.\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"Ermin (ERMN) is an oligodendrocyte-specific cytoskeletal protein localized to the outer cytoplasmic lip of the myelin sheath and paranodal loops in mature nerve. In cultured oligodendrocytes, Ermin concentrates at the tips of F-actin-rich processes ('Ermin spikes'). Ectopic expression of full-length Ermin, but not of a mutant lacking its actin-binding domain, induced numerous cell protrusions and pronounced morphological changes, demonstrating that the actin-binding domain is required for cytoskeletal rearrangement activity.\",\n      \"method\": \"Microarray expression profiling of oligodendrocyte-ablated mice, immunolocalization in mature nerve and cultured oligodendrocytes, ectopic expression of wild-type and actin-binding domain deletion mutants in cultured cells\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — domain-deletion mutagenesis combined with cellular morphology readout and in vivo localization; foundational mechanistic study replicated by subsequent independent labs\",\n      \"pmids\": [\"16421295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Human Ermin (hErmin) promotes arborization and cytoskeletal rearrangement in cultured COS-7 cells when expressed as full-length protein, but truncated mutants lacking the actin-binding domain fail to do so, confirming that the actin-binding domain is the functional effector domain for morphological changes.\",\n      \"method\": \"Ectopic expression of full-length and truncated hErmin constructs in COS-7 cells with morphological readout\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-deletion mutagenesis with clear functional readout, single lab replicating the founding observation with human ortholog\",\n      \"pmids\": [\"20934411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ERMN is a primary target of disrupted folate metabolism caused by sevoflurane anesthesia. Sevoflurane downregulates thymidylate synthase (TYMS), reducing folate availability, which epigenetically suppresses ERMN expression and impairs myelination. Restoration of ERMN expression via brain-specific AAV-PHP.EB delivery, or systemic folic acid supplementation, rescued myelination deficits and alleviated cognitive impairment in mice, placing ERMN downstream of the TYMS–folate–epigenetic axis in developmental myelination.\",\n      \"method\": \"Transcriptome profiling and genome-wide DNA methylation analysis in sevoflurane-exposed rhesus macaques and mice; AAV-mediated ERMN rescue in vivo; folic acid supplementation rescue; cognitive behavioral testing\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (transcriptomics, methylomics, in vivo rescue with AAV and pharmacological intervention) across two species with clear functional endpoints\",\n      \"pmids\": [\"31060905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Ermin maintains myelin sheath integrity and is required for normal saltatory conduction. Aged Ermn-knockout mice develop aberrant myelin architecture (splitting of myelin layers, peeling from axons, breakdown of myelinated fibers) and impaired motor coordination. Mechanistically, Ermin associates with the myosin phosphatase Rho-interacting protein (Mprip/p116RIP) and inactivates RhoA, a GTPase controlling cytoskeletal rearrangement in differentiating oligodendrocytes. Ermn knockout also accelerated cuprizone-induced demyelination.\",\n      \"method\": \"Constitutive Ermn-knockout mouse generation; electron microscopy of myelin ultrastructure; motor coordination behavioral assays; cuprizone demyelination model; co-immunoprecipitation of Ermin with p116RIP; RhoA activity assays\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP identifying p116RIP as binding partner, RhoA activity assay, KO mouse with defined ultrastructural and behavioral phenotypes, multiple orthogonal methods in one study\",\n      \"pmids\": [\"32530539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Loss of Ermin causes de-compacted and fragmented myelin sheaths and slower nerve conduction in vivo. RNA-seq of the corpus callosum of aged Ermin-deficient mice revealed inflammatory activation, corroborated by increased microgliosis and astrogliosis. Ermin-knockout mice show increased susceptibility to immune-mediated (EAE) demyelination. A rare inactivating ERMN mutation was identified in multiple sclerosis patients, supporting an 'inside-out' model of inflammatory dysmyelination initiated by myelin instability.\",\n      \"method\": \"Ermn-knockout mouse model; electrophysiology (nerve conduction velocity); RNA-seq of corpus callosum; immunohistochemistry for microglia and astrocyte markers; EAE (experimental autoimmune encephalomyelitis) susceptibility assay; human ERMN sequencing in MS patients\",\n      \"journal\": \"Brain pathology (Zurich, Switzerland)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse with electrophysiological, transcriptomic, and histological phenotypes plus human genetic evidence; multiple orthogonal methods\",\n      \"pmids\": [\"35285112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Rare genetic variants causing hypomethylation (meSNVs) at the ERMN locus are significantly associated with autism spectrum disorder (ASD). Resequencing revealed a significant load of deleterious mutations in ERMN in ASD cases compared with controls, and cis-acting methylation changes correlated with altered ERMN expression, implicating epigenetic regulation of ERMN in ASD susceptibility.\",\n      \"method\": \"Genome-wide methylation array (450K Illumina) in ASD patients vs. controls; blood RNA-seq; case-control association study; targeted resequencing of ERMN\",\n      \"journal\": \"Translational psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — multiple genomic methods in a sizeable cohort but no direct functional experiment on the protein mechanism; establishes epigenetic regulation of ERMN but not the protein's mechanistic action\",\n      \"pmids\": [\"27404287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In the cuprizone demyelination/remyelination mouse model, the density of Ermin-immunopositive oligodendrocytes decreases after one week of cuprizone exposure and increases during remyelination in the corpus callosum. In MS lesions, the proportion of ermin+ cells relative to Nogo-A+ cells is higher in remyelinated areas than in non-remyelinated or normal-appearing white matter, indicating that a relatively higher proportion of Ermin immunopositivity marks recent or ongoing remyelination.\",\n      \"method\": \"Cuprizone mouse model with time-course immunohistochemistry; immunostaining of MS post-mortem tissue with Ermin, Nogo-A, O4, and O1 markers\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — quantitative in vivo localization experiment with functional context (remyelination state) replicated in both animal model and human tissue, single lab\",\n      \"pmids\": [\"34437581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ERMN mRNA expression is significantly downregulated in peripheral blood of ASD patients compared with healthy controls, with the effect reaching significance specifically in male subjects, supporting a role for ERMN dysregulation in ASD pathogenesis.\",\n      \"method\": \"Quantitative real-time PCR of ERMN in peripheral blood of ASD patients and matched healthy controls\",\n      \"journal\": \"Frontiers in molecular neuroscience\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single method (qRT-PCR), expression data only, no direct mechanistic experiment on the protein\",\n      \"pmids\": [\"34349621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ERMN expression is significantly decreased in peripheral blood leukocytes of relapsing-remitting multiple sclerosis (RR-MS) patients compared with healthy controls, consistent with Ermin's proposed role in maintaining myelination.\",\n      \"method\": \"Quantitative RT-PCR of ERMN transcript in peripheral blood of RR-MS patients vs. controls\",\n      \"journal\": \"Metabolic brain disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single method (qRT-PCR), expression correlation only, no direct mechanistic protein experiment\",\n      \"pmids\": [\"31123898\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ERMN encodes Ermin, an oligodendrocyte-specific actin-binding cytoskeletal protein localized to the outer cytoplasmic lip of the myelin sheath and paranodal loops; its actin-binding domain is required for inducing cell protrusions and cytoskeletal rearrangements in oligodendrocytes, and Ermin maintains myelin integrity by binding the myosin phosphatase co-factor p116RIP (Mprip) and inactivating RhoA, with loss of Ermin causing myelin decompaction, inflammatory gliosis, impaired nerve conduction, and increased susceptibility to demyelination, while its expression is epigenetically regulated downstream of the folate–TYMS axis during developmental myelination.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ERMN encodes Ermin, an oligodendrocyte-specific actin-binding cytoskeletal protein that concentrates at the outer cytoplasmic lip of the myelin sheath and at paranodal loops, where it drives the cytoskeletal rearrangements underlying myelin morphogenesis and maintenance [#0]. In cultured cells, Ermin localizes to the tips of F-actin-rich processes and its actin-binding domain is required to induce cell protrusions and arborization; deletion of this domain abolishes the morphological activity in both rodent and human orthologs [#0, #1]. Mechanistically, Ermin associates with the myosin phosphatase Rho-interacting protein Mprip/p116RIP and inactivates RhoA, linking it to GTPase-controlled cytoskeletal remodeling in differentiating oligodendrocytes [#3]. Loss of Ermin produces de-compacted, fragmented, and split myelin, slowed saltatory nerve conduction, motor deficits, inflammatory gliosis, and heightened susceptibility to cuprizone- and immune-mediated (EAE) demyelination, defining Ermin as a maintainer of myelin integrity whose failure can initiate inflammatory dysmyelination [#3, #4]. Ermin immunopositivity tracks active remyelination in both the cuprizone model and human MS lesions [#6], and a rare inactivating ERMN mutation has been identified in multiple sclerosis patients, supporting an 'inside-out' model of demyelination driven by intrinsic myelin instability [#4]. ERMN expression is epigenetically regulated downstream of the TYMS–folate axis during developmental myelination, with folate disruption suppressing ERMN and impairing myelination that is rescued by restoring ERMN or supplementing folate [#2].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Establishing what Ermin is and how it acts: identifying it as an oligodendrocyte-specific protein whose actin-binding domain drives cytoskeletal rearrangement answered whether ERMN had a defined cellular function in myelinating cells.\",\n      \"evidence\": \"Microarray profiling of oligodendrocyte-ablated mice, immunolocalization in nerve and cultured oligodendrocytes, and ectopic expression of wild-type vs. actin-binding-domain-deletion mutants\",\n      \"pmids\": [\"16421295\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify direct binding partners beyond F-actin association\", \"Mechanism linking actin binding to myelin assembly in vivo not yet defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Confirming that the human ortholog retains the same domain-dependent activity established conservation of Ermin's cytoskeletal effector function across species.\",\n      \"evidence\": \"Ectopic expression of full-length and truncated human Ermin constructs in COS-7 cells with morphological readout\",\n      \"pmids\": [\"20934411\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Performed in a non-oligodendrocyte heterologous cell line\", \"No identification of binding partners or signaling output\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linking ERMN epigenetic regulation to a neurodevelopmental disorder tested whether ERMN dysregulation has disease relevance beyond myelin biology.\",\n      \"evidence\": \"Genome-wide methylation array, blood RNA-seq, case-control association, and targeted resequencing of ERMN in ASD cohorts\",\n      \"pmids\": [\"27404287\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional experiment connecting methylation changes to protein-level mechanism\", \"Association does not establish causality in ASD\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Placing ERMN downstream of the TYMS–folate–epigenetic axis explained how environmental and metabolic perturbation suppresses myelination through ERMN.\",\n      \"evidence\": \"Transcriptomics and methylomics in sevoflurane-exposed macaques and mice, with AAV-mediated ERMN rescue and folic acid supplementation plus cognitive testing\",\n      \"pmids\": [\"31060905\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise epigenetic mark and machinery suppressing ERMN not pinpointed\", \"Direct molecular link between ERMN restoration and myelin repair mechanism not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Correlating reduced ERMN transcript with relapsing-remitting MS provided a peripheral biomarker consistent with its myelin-maintenance role.\",\n      \"evidence\": \"Quantitative RT-PCR of ERMN in peripheral blood leukocytes of RR-MS patients vs. controls\",\n      \"pmids\": [\"31123898\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single-method expression correlation only\", \"Peripheral blood may not reflect CNS Ermin biology\", \"No mechanistic link to disease causation\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defining the in vivo loss-of-function phenotype and identifying the Mprip/p116RIP–RhoA axis revealed the signaling mechanism by which Ermin maintains myelin.\",\n      \"evidence\": \"Constitutive Ermn-knockout mice with EM ultrastructure, motor assays, cuprizone demyelination, reciprocal Co-IP with p116RIP, and RhoA activity assays\",\n      \"pmids\": [\"32530539\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the Ermin–p116RIP interaction unknown\", \"How RhoA inactivation is spatially coupled to myelin compaction not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing Ermin immunopositivity tracks remyelination state established it as an in vivo marker of active myelin repair.\",\n      \"evidence\": \"Time-course immunohistochemistry in the cuprizone model and immunostaining of MS post-mortem lesions with Ermin, Nogo-A, O4, and O1 markers\",\n      \"pmids\": [\"34437581\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Correlative marker association, not a functional test of Ermin in remyelination\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Documenting reduced ERMN transcript in ASD peripheral blood, with male-specific significance, reinforced the disease-association signal from the methylation study.\",\n      \"evidence\": \"Quantitative real-time PCR of ERMN in peripheral blood of ASD patients vs. matched controls\",\n      \"pmids\": [\"34349621\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single-method expression data with no protein-level mechanism\", \"Peripheral blood relevance to CNS uncertain\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Connecting myelin instability to inflammatory activation and human genetic risk supported an 'inside-out' model in which intrinsic Ermin loss initiates demyelinating disease.\",\n      \"evidence\": \"Ermn-knockout mice with nerve conduction electrophysiology, corpus callosum RNA-seq, gliosis immunohistochemistry, EAE susceptibility, and ERMN sequencing in MS patients\",\n      \"pmids\": [\"35285112\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causality of the identified ERMN mutation in MS not functionally proven\", \"Mechanism linking myelin decompaction to inflammatory recruitment not detailed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How Ermin's actin-binding and p116RIP/RhoA signaling are mechanistically coupled to myelin compaction, and how its loss is sensed to trigger neuroinflammation, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model of Ermin or its complexes\", \"Sensor/effector pathway linking myelin instability to gliosis undefined\", \"Functional validation of human ERMN disease mutations lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MPRIP\", \"RHOA\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}